[Development of influenza vaccines against newly emerging A/H5N1 virus].
Emergence of highly virulent influenza A/H5N1 viruses in Hong Kong in 1997 posed a threat of pandemic and brought an urgent need to develop a suitable seed virus for vaccine production. The virulence of the H5N1 viruses to chicken embryos should hamper the efficient production of the vaccine. In addition, potential virulence to humans raised safety issue in manufacturing vaccine. Toward vaccine development, one approach is to use an avirulent avian influenza virus antigenically similar to the virulent ones as a surrogate vaccine strain. The other approach is based on the attenuation of pathogenicity of virulent H5N1 virus by genetic engineering of the hemagglutinin gene and selection of a gene constellation. The reverse genetics technique can make the latter approach possible. Candidate strains suitable for vaccine production could be prepared by using either approach.
Itamura
S
S
Department of Virology I, National Institute of Infectious Diseases.
D000818:Animals; D002642:Chick Embryo; D005814:Genes, Viral; D005818:Genetic Engineering; D006388:Hemagglutinins / Q000737:chemistry / Q000235:genetics; D006801:Humans; D053124:Influenza A Virus, H5N1 Subtype; D009980:Influenza A virus / Q000235:genetics / Q000276:immunology; D007252:Influenza Vaccines; D007251:Influenza, Human / Q000635:transmission; D014613:Vaccines, Attenuated; D014774:Virulence
D006388:Hemagglutinins; D007252:Influenza Vaccines; D014613:Vaccines, Attenuated